366 related articles for article (PubMed ID: 26175541)
1. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
[TBL] [Abstract][Full Text] [Related]
2. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
3. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Pandit-Taskar N; O'Donoghue JA; Beylergil V; Lyashchenko S; Ruan S; Solomon SB; Durack JC; Carrasquillo JA; Lefkowitz RA; Gonen M; Lewis JS; Holland JP; Cheal SM; Reuter VE; Osborne JR; Loda MF; Smith-Jones PM; Weber WA; Bander NH; Scher HI; Morris MJ; Larson SM
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2093-105. PubMed ID: 25143071
[TBL] [Abstract][Full Text] [Related]
4. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Ciarallo A; Mena E; Blackford A; Nadal R; Antonarakis ES; Eisenberger MA; Carducci MA; Ross AE; Kantoff PW; Holt DP; Dannals RF; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2016 Jan; 57(1):46-53. PubMed ID: 26493203
[TBL] [Abstract][Full Text] [Related]
7. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
[TBL] [Abstract][Full Text] [Related]
8. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
Morris MJ; Akhurst T; Osman I; Nunez R; Macapinlac H; Siedlecki K; Verbel D; Schwartz L; Larson SM; Scher HI
Urology; 2002 Jun; 59(6):913-8. PubMed ID: 12031380
[TBL] [Abstract][Full Text] [Related]
9. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using
Carrasquillo JA; Fine BM; Pandit-Taskar N; Larson SM; Fleming SE; Fox JJ; Cheal SM; O'Donoghue JA; Ruan S; Ragupathi G; Lyashchenko SK; Humm JL; Scher HI; Gönen M; Williams SP; Danila DC; Morris MJ
J Nucl Med; 2019 Nov; 60(11):1517-1523. PubMed ID: 31053681
[TBL] [Abstract][Full Text] [Related]
10. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
11. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
12. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial.
Suzuki H; Inoue Y; Fujimoto H; Yonese J; Tanabe K; Fukasawa S; Inoue T; Saito S; Ueno M; Otaka A
Jpn J Clin Oncol; 2016 Feb; 46(2):152-62. PubMed ID: 26732384
[TBL] [Abstract][Full Text] [Related]
14. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
Pandit-Taskar N; O'Donoghue JA; Morris MJ; Wills EA; Schwartz LH; Gonen M; Scher HI; Larson SM; Divgi CR
J Nucl Med; 2008 Jul; 49(7):1066-74. PubMed ID: 18552139
[TBL] [Abstract][Full Text] [Related]
15. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.
Osborne JR; Green DA; Spratt DE; Lyashchenko S; Fareedy SB; Robinson BD; Beattie BJ; Jain M; Lewis JS; Christos P; Larson SM; Bander NH; Scherr DS
J Urol; 2014 May; 191(5):1439-45. PubMed ID: 24135437
[TBL] [Abstract][Full Text] [Related]
16. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Wang S; Li J; Hua J; Su Y; Beckford-Vera DR; Zhao W; Jayaraman M; Huynh TL; Zhao N; Wang YH; Huang Y; Qin F; Shen S; Gioeli D; Dreicer R; Sriram R; Egusa EA; Chou J; Feng FY; Aggarwal R; Evans MJ; Seo Y; Liu B; Flavell RR; He J
Clin Cancer Res; 2021 Mar; 27(5):1305-1315. PubMed ID: 33293372
[TBL] [Abstract][Full Text] [Related]
17. Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.
Hintz HM; Gallant JP; Vander Griend DJ; Coleman IM; Nelson PS; LeBeau AM
Clin Cancer Res; 2020 Sep; 26(18):4882-4891. PubMed ID: 32636317
[TBL] [Abstract][Full Text] [Related]
18. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
19. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
20. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
